STORY FROM: Drugs & Medical Devices

Design Defect, Failure-To-Warn Claims in Jardiance Case Not Preempted, Ind. Federal Judge Rules

INDIANAPOLIS — An Indiana federal judge has allowed failure-to-warn and design defect claims to proceed against Boehringer Ingelheim in a Jardiance action, finding they are not preempted because Boehringer did not show that the FDA would have rejected any proposed changes to the label.

However, in the Sept. 7 opinion, Judge Sarah E. Baker of the U.S. District Court for the Southern District of Indiana dismissed the claims against defendant Eli Lilly & Co., finding they are preempted because Lilly is not the Jardiance New Drug Application holder and thus could not unilaterally make changes to the drug’s label.

Tanya ...

Associated Law Firms
Hovde Dassow & Deets
Ice Miller
Katz Korin Cunningham
Pepper Hamilton
SIdley Austin

Associated Documents

Registered User Login